These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 26451024)

  • 21. The THRIVE score predicts symptomatic intracerebral hemorrhage after intravenous tPA administration in SITS-MOST.
    Flint AC; Gupta R; Smith WS; Kamel H; Faigeles BS; Cullen SP; Rao VA; Bath PM; Wahlgren N; Ahmed N; Donnan GA;
    Int J Stroke; 2014 Aug; 9(6):705-10. PubMed ID: 25042855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of off-label stroke treatment with tissue plasminogen activator.
    Kvistad CE; Logallo N; Thomassen L; Waje-Andreassen U; Brøgger J; Naess H
    Acta Neurol Scand; 2013 Jul; 128(1):48-53. PubMed ID: 23311439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transition of European Cooperative Acute Stroke Study III results to clinical practice: ninety-day outcomes in a US cohort.
    Cronin CA; Langenberg P; Dutta TM; Kittner SJ
    Stroke; 2013 Dec; 44(12):3544-6. PubMed ID: 24092551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validation of FLAIR hyperintense lesions as imaging biomarkers to predict the outcome of acute stroke after intra-arterial thrombolysis following intravenous tissue plasminogen activator.
    Chung JW; Kim KJ; Noh WY; Jang MS; Yang MH; Han MK; Kwon OK; Jung C; Kim JH; Oh CW; Lee JS; Lee J; Bae HJ
    Cerebrovasc Dis; 2013; 35(5):461-8. PubMed ID: 23735898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of acute ischaemic stroke with thrombolysis or thrombectomy in patients receiving anti-thrombotic treatment.
    Diener HC; Foerch C; Riess H; Röther J; Schroth G; Weber R
    Lancet Neurol; 2013 Jul; 12(7):677-88. PubMed ID: 23726849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age.
    Kono S; Deguchi K; Morimoto N; Kurata T; Yamashita T; Ikeda Y; Narai H; Manabe Y; Takao Y; Kawada S; Kashihara K; Takehisa Y; Inoue S; Kiriyama H; Abe K
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1175-83. PubMed ID: 23507462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does sex influence the response to intravenous thrombolysis in ischemic stroke?: answers from safe implementation of treatments in Stroke-International Stroke Thrombolysis Register.
    Lorenzano S; Ahmed N; Falcou A; Mikulik R; Tatlisumak T; Roffe C; Wahlgren N; Toni D;
    Stroke; 2013 Dec; 44(12):3401-6. PubMed ID: 24172579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of symptomatic intracranial haemorrhage in off-label thrombolysis: an analysis of the Safe Implementation of Treatments in Stroke registry.
    Mundiyanapurath S; Hees K; Ahmed N; Wahlgren N; Uhlmann L; Kieser M; Ringleb PA; Hacke W; Nagel S
    Eur J Neurol; 2018 Feb; 25(2):340-e11. PubMed ID: 29105904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombolysis with alteplase for acute ischemic stroke: review of SITS-MOST and other Phase IV studies.
    Külkens S; Hacke W
    Expert Rev Neurother; 2007 Jul; 7(7):783-8. PubMed ID: 17610385
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT).
    Yamaguchi T; Mori E; Minematsu K; Nakagawara J; Hashi K; Saito I; Shinohara Y;
    Stroke; 2006 Jul; 37(7):1810-5. PubMed ID: 16763187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Time to recanalization and risk of symptomatic intracerebral haemorrhage in patients treated with intravenous thrombolysis.
    Dorado L; Millán M; Pérez de la Ossa N; Guerrero C; Gomis M; Aleu A; López-Cancio E; Cuadras P; Dávalos A
    Eur J Neurol; 2012 Sep; 19(9):1251-5. PubMed ID: 22568604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TESPI (Thrombolysis in Elderly Stroke Patients in Italy): a randomized controlled trial of alteplase (rt-PA) versus standard treatment in acute ischaemic stroke in patients aged more than 80 years where thrombolysis is initiated within three hours after stroke onset.
    Lorenzano S; Toni D;
    Int J Stroke; 2012 Apr; 7(3):250-7. PubMed ID: 22292526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aphasia predicts unfavorable outcome in mild ischemic stroke patients and prompts thrombolytic treatment.
    Nesi M; Lucente G; Nencini P; Fancellu L; Inzitari D
    J Stroke Cerebrovasc Dis; 2014 Feb; 23(2):204-8. PubMed ID: 23352114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effectiveness of thrombolysis with intravenous alteplase for acute ischemic stroke in daily practice.
    Dirks M; Niessen LW; van Wijngaarden J; Koudstaal PJ; Franke CL; van Oostenbrugge RJ; Dippel DW;
    Int J Stroke; 2012 Jun; 7(4):289-92. PubMed ID: 22168317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal impairment reduces the efficacy of thrombolytic therapy in acute ischemic stroke.
    Power A; Epstein D; Cohen D; Bathula R; Devine J; Kar A; Taube D; Duncan N; Ames D
    Cerebrovasc Dis; 2013; 35(1):45-52. PubMed ID: 23428996
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative effects of low-dose versus standard-dose alteplase in ischemic patients with prior stroke and/or diabetes mellitus: The ENCHANTED trial.
    Chen G; Wang X; Robinson TG; Pikkemaat M; Lindley RI; Zhou S; Ping L; Liu W; Liu L; Chalmers J; Anderson CS;
    J Neurol Sci; 2018 Apr; 387():1-5. PubMed ID: 29571842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unequal access to treatment with intravenous alteplase for women with acute ischemic stroke.
    de Ridder I; Dirks M; Niessen L; Dippel D;
    Stroke; 2013 Sep; 44(9):2610-2. PubMed ID: 23887843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sex Differences and Functional Outcome After Intravenous Thrombolysis.
    Spaander FH; Zinkstok SM; Baharoglu IM; Gensicke H; Polymeris A; Traenka C; Hametner C; Ringleb P; Curtze S; Martinez-Majander N; Aarnio K; Nolte CH; Scheitz JF; Leys D; Hochart A; Padjen V; Kägi G; Pezzini A; Michel P; Bill O; Zini A; Engelter ST; Nederkoorn PJ;
    Stroke; 2017 Mar; 48(3):699-703. PubMed ID: 28143921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous recombinant tissue plasminogen activator for acute stroke in Poland: an analysis based on the Safe Implementation of Thrombolysis in Stroke (SITS) Registry.
    Kobayashi A; Czlonkowska A; Ahmed N; Romanowicz S; Glonek M; Nyka WM; Opala G; Wahlgren N;
    Acta Neurol Scand; 2010 Oct; 122(4):229-36. PubMed ID: 19919643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Intravenous thrombolysis for ischemic stroke: Experience in 54 patients].
    Guevara O C; Bulatova K; Aravena F; Caba S; Monsalve J; Lara H; Nieto E; Navarrete I; Morales M
    Rev Med Chil; 2016 Apr; 144(4):434-41. PubMed ID: 27401375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.